Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT Combined With SHR-1701 and Nab-Paclitaxel Plus Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic PDAC
NCT07845565Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Fecal Microbiota Transplantation Capsule in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Median Progression-Free Survival at 12 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07845565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07845565.